Question · Q4 2025
Ed Wu requested clarification on Aytu BioPharma's pro forma operating expenses of $39 million and the planned distribution of the $10 million additional investment for the Exua launch throughout the fiscal year.
Answer
CFO Ryan Selhorn clarified that the pro forma annual operating expense is about $36.3 million, with the $10 million Exua launch investment starting in the December quarter (Q2 fiscal 2026). He estimated that approximately 50% of this investment would be spent in Q2, with the remaining 50% distributed across Q3 and Q4, primarily covering sales representatives and marketing materials.